Severe graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with residual mogamulizumab concentration
Letter to the Editor
- 79 Downloads
Compliance with ethical standards
Conflict of interest
None of the authors have any financial conflicts of interest related with this work.
- 3.Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, et al. Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality. J Clin Oncol. 2016;34:3426–33.CrossRefPubMedGoogle Scholar
© The Japanese Society of Hematology 2018